NCT00539591 2025-12-23
Phase II Study Incorporating Pegylated Interferon In the Treatment For Children With High-Risk Melanoma
St. Jude Children's Research Hospital
Phase 2 Active not recruiting
Clinical Trials
26 trialsNCT01119508 2024-06-06
Ipilimumab + Temozolomide in Metastatic Melanoma
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00591370 2023-07-25
Phase II Trial of Extended-Dosing Temozolomide in Patients With Melanoma
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT00667953 2023-03-30
Study of Temzolomide and Gleevec in Advanced Melanoma
Abramson Cancer Center at Penn Medicine
Phase 1/2 Terminated
NCT00602576 2022-06-14
Temozolomide and Sorafenib in Treating Patients With Metastatic or Unresectable Melanoma
Abramson Cancer Center at Penn Medicine
Phase 2 Completed
NCT02288897 2022-01-19
PV-10 vs Chemotherapy or Oncolytic Viral Therapy for Treatment of Locally Advanced Cutaneous Melanoma
Provectus Pharmaceuticals
Phase 3 Terminated
NCT01328535 2020-10-22
Individualized Temozolomide in Treating Patients With Stage IV Melanoma That Cannot Be Removed By Surgery
Mayo Clinic
Phase 2 Completed
NCT00505635 2020-09-24
Biochemotherapy With Temozolomide for Metastatic Melanoma
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT00525031 2020-09-23
Temozolomide Alone or With Pegylated Interferon-Alpha 2b (PGI) in Melanoma Patients
M.D. Anderson Cancer Center
Phase 2 Completed
NCT01590082 2020-09-02
Doxycycline, Temozolomide and Ipilimumab in Melanoma
M.D. Anderson Cancer Center
Phase 1/2 Terminated
NCT01704287 2020-05-18
KEYNOTE 002
Merck Sharp & Dohme LLC
Phase 2 Completed
NCT01196416 2019-11-18
Gamma-secretase/Notch Signalling Pathway Inhibitor RO4929097 in Combination With Cisplatin, Vinblastine, and Temozolomide in Treating Patients With Recurrent or Metastatic Melanoma
National Cancer Institute (NCI)
Phase 1/2 Completed
NCT00301067 2019-06-04
Phase I/II Study of High-Dose Calcitriol Plus Temodar for Patients With Metastatic Melanoma
Northwestern University
Phase 1/2 Completed
NCT01124734 2019-02-12
High Dose Interleukin-2 Followed by Intermittent Low Dose Temozolomide in Patients With Melanoma
Milton S. Hershey Medical Center
Phase 2 Completed
NCT00804908 2018-06-06
A Study Evaluating Efficacy of ABT-888 in Combination With Temozolomide in Metastatic Melanoma
AbbVie
Phase 2 Completed
NCT00626405 2018-05-01
Bevacizumab and Temozolomide or Bevacizumab and Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Carboplatin in Treating Patients With Stage IV Malignant Melanoma That Cannot Be Removed by Surgery
Alliance for Clinical Trials in Oncology
Phase 2 Completed
NCT01009515 2017-10-18
Carboplatin, Paclitaxel, and Temozolomide for Patients With Metastatic Melanoma
New Mexico Cancer Research Alliance
Phase 2 Terminated
NCT00715793 2017-10-03
UPCI-07-008
University of Pittsburgh
Phase 1/2 Completed
NCT00521001 2017-08-14
Temozolomide and Everolimus in Treating Patients With Stage IV Melanoma That Cannot be Removed by Surgery
Alliance for Clinical Trials in Oncology
Phase 2 Completed
NCT00925132 2017-07-02
Treatment of Resistant Metastatic Melanoma Using Decitabine, Temozolomide and Panobinostat
University of Iowa
Phase 1/2 Terminated
NCT00091572 2017-06-06
Temozolomide Versus Dacarbazine in Stage IV Metastatic Melanoma (Study P03267)
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT00588341 2016-02-01
Phase II Trial of Neoadjuvant Temozolomide in Melanoma Patients With Palpable Stage III or IV Disease Undergoing Complete Surgical Resection
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT00673361 2016-01-13
Pilot Trial of "Chemo-Switch" Regimen to Treat Advanced Melanoma
Duke University
Phase 2 Terminated
NCT00568451 2015-12-30
Paclitaxel and Carboplatin or Temozolomide in Treating Patients With Stage IV Melanoma
Mayo Clinic
Phase 2 Terminated
NCT00885534 2015-05-06
Genetic Variates of Response to Cisplatin, Vinblastine, and Temozolomide (CVT) in Patients With Metastatic Melanoma
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT00512798 2012-10-02
Bortezomib and Temozolomide in Treating Patients With Advanced Refractory Solid Tumors or Melanoma
Vanderbilt-Ingram Cancer Center
Phase 1/2 Terminated